Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia

Published:2017-06 Issue: Volume:120 Page:138-145
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Harivenkatesh Natarajan,Kumar Lalit,Bakhshi Sameer,Sharma Atul,Kabra Madhulika,Velpandian Thirumurthy,Gogia Ajay,Shastri Shivaram S.,Biswas Nihar Ranjan,Gupta Yogendra Kumar

Publisher

Elsevier BV

Subject

Pharmacology

Reference40 articles.

1. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management;Jabbour;Am. J. Hematol.,2012

2. Current status of imatinib as frontline therapy for chronic myeloid leukemia;Marin;Semin. Hematol.,2010

3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia;Baccarani;Blood,2013

4. Clinical pharmacokinetics of imatinib;Peng;Clin. Pharmacokinet.,2005

5. Drug transporters and imatinib treatment: implications for clinical practice;Eechoute;Clin. Cancer Res.,2011

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients;Pharmaceutics;2024-06-19

2. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia;International Immunopharmacology;2024-05

3. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

4. Analysis of drug transporter gene polymorphisms in an elderly patient with chronic myeloid leukemia successfully treated with intermittent low‐dose dasatinib;Geriatrics & Gerontology International;2023-11-03

5. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies;Hematology;2023-04-20